Holen Sie sich die Stockscreener-App
2.15
3.15%
-0.07
Handel nachbörslich:
2.18
0.03
+1.40%
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study - MyChesCo
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Canada
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement. - Bitget
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Reports 2025 Results, Advances Buntanetap Trials - MyChesCo
If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Rankings: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Meme Stocks: Will Annovis Bio Inc benefit from rising consumer demand2026 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring - Intellectia AI
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring By Investing.com - Investing.com India
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - The Manila Times
Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Alzheimer’s oral drug buntanetap enters pivotal trial, 3‑year PD study - Stock Titan
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat
Annovis Bio, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Announces Two Presentations at the AD/PD 2026 International Conference - Bitget
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - The Manila Times
New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026 - Stock Titan
AI Stocks: Will Annovis Bio Inc. benefit from rising consumer demandTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS
ANVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annovis nears FDA threshold for Alzheimer's drug as CEO eyes spring milestone - The Business Journals
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):